Lactitol

Lactitol: A Comprehensive Reference Article

1. Identity: Chemical Names, Origin, and Physical Forms

1.1 Chemical and Synonymous Names

Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from lactose. More precisely, it is a disaccharide sugar alcohol derived from lactose by reduction of its glucose moiety, yielding the systematic name 4-O-(β-D-galactopyranosyl)-D-glucitol. Lactitol is also called lactositol, lactit, and lactobiosit, and consists of galactose and glucitol. Structurally, it is a glycosyl alditol consisting of beta-D-galactopyranose and D-glucitol joined by a 1→4 glycosidic bond. The CAS registry number for the anhydrous form is 585-86-4, while the monohydrate carries CAS number 81025-04-9.

1.2 Natural Occurrence and Production

Lactitol is not found in nature and can only be produced via catalytic hydrogenation of lactose. It is obtained by catalytic hydrogenation of lactose from cow's milk, affording an approximately 95% pure product. The process converts the reducing glucose end of the lactose disaccharide to a sorbitol residue, rendering the molecule non-reducing. Lactitol is thus a poorly digestible carbohydrate, a sugar alcohol composed of galactose and sorbitol, produced by hydrogenation of lactose, which is derived from whey.

1.3 Physical and Chemical Characteristics

Lactitol is an odorless, colorless, sweet, nonhygroscopic, and stable sugar alcohol. As it lacks a reactive carbonyl group, which is characteristic of sugar molecules, it does not participate in Maillard browning reactions with amino groups. It occurs in both monohydrate and dihydrate crystalline forms as pure products with good flowability. Lactitol is stable under both alkaline and acid conditions and at high temperatures likely to be encountered during food processing. Its melting point is 146°C and it is very soluble in water.

Lactitol and maltitol are classified as disaccharide alcohols, since they contain one intact sugar, unlike simpler monosaccharide sugar alcohols. Lactitol is best known as a nutritive sweetener whose relative sweetness is between 30 and 40% that of sucrose. Regulatory agencies such as European labeling authorities and the FDA assign it a caloric value of 2.4 and 2.0 kcal/g, respectively, corresponding to a reduction of 48–40% with respect to sucrose.

1.4 Common Forms and Preparations

Lactitol is a sugar alcohol that can exist in different crystalline forms. It is a versatile ingredient employed not only to deliver sweetness at low caloric value, but also to assist food formulation as a bulking agent, humectant, cryoprotectant, and prebiotic source. Lactitol is used extensively in formulating bakery, chocolate, confectionery, dessert, and chewing gum products, and as a delivery agent with pharmaceutical purposes. In pharmaceutical settings, it is available as an oral powder for solution; the FDA-approved prescription product is an off-white crystalline powder for oral solution. In the European Union, lactitol is approved as a food additive with the code E966 and used as a synthetic sweetener.

2. Historical Use and Development

2.1 Discovery and Early History

The first report on the synthesis of lactitol dates back to the early 1920s. It was first discovered in 1920, but it was not until the 1980s when it was first used in foods as a reduced-calorie sweetener. Unlike most plant-based traditional medicinal ingredients, lactitol has no pre-modern ethnobotanical history; it is a fully synthetic derivative of dairy-derived lactose and its medicinal and food-additive applications are entirely products of twentieth-century food science and clinical pharmacology.

2.2 Regulatory and Commercial History

Over the last decades, lactitol has emerged into a multipurpose ingredient, from low-caloric sweetness to coating material in chewing gums, summarizing relevant advancements over approximately 100 years of lactitol history. Its laxative application in hepatic encephalopathy was among the first clinical uses to be rigorously investigated. Non-absorbable disaccharides (NADs), such as lactulose (beta-galactosidofructose) and lactitol (beta-galactosidosorbitol), have been mainstays of treatment of hepatic encephalopathy since first described by Johannes Bircher in 1966.

The EU Scientific Committee on Food considered new data on metabolism and gastric effects in 1988, but maintained its previous evaluation from 1984. At the international level, all the polyols in the Codex General Standard for Food Additives—including lactitol—have been adopted as additives "permitted for use in food in general, unless otherwise specified, in accordance with GMP," with an ADI (acceptable daily intake) of "not specified." In the United States, the FDA approved lactitol (Pizensy, Braintree Laboratories) as an osmotic laxative indicated for the treatment of chronic idiopathic constipation in adults in February 2020.

Lactitol is recognized as safe by the World Health Organization's Joint Expert Committee on Food Additives (JECFA). The U.S. Food and Drug Administration classifies sugar alcohols as "generally recognized as safe" (GRAS). They are approved as food additives and are recognized as not contributing to tooth decay or causing increases in blood glucose.

3. Key Constituents, Pharmacokinetics, and Mechanisms of Action

3.1 Chemical Structure as the Active Unit

Unlike complex botanical supplements with multiple phytochemical constituents, lactitol is a single pure chemical entity. It is not found in nature and can only be produced via catalytic hydrogenation of lactose. Chemically, it is a sugar alcohol that can exist in different crystalline forms. Its entire pharmacological activity derives from the intact disaccharide alcohol structure, which resists digestion in the small intestine.

3.2 Non-absorption in the Small Intestine

In vitro studies with galactosidase-containing enzyme preparations have demonstrated that lactitol is hydrolyzed only very slowly. In incubations with human intestinal biopsies, the human intestinal mucosa does not exhibit any significant disaccharidase activity with lactitol as a substrate. The hydrolytic activities towards lactitol and isomalt were only 1.3% of those towards lactose and isomaltulose, respectively. These observations indicate that lactitol is the most slowly digested disaccharide sugar alcohol.

Only about 2% of the ingested lactitol is digested in the small intestine to glucose and sorbitol, which are absorbed; the rest passes to the large intestine where it is fermented by colonic bacteria to gases, short-chain fatty acids (SCFA), and lactic acid, which are partly consumed by bacteria and partly absorbed. Some studies have estimated that only 0.6% of an oral dose of lactitol is excreted in the urine.

3.3 Osmotic Laxative Mechanism

Lactitol, produced by hydrogenation of lactose, is an osmotic disaccharide laxative that increases osmotic pressure in the intestinal lumen, resulting in increased fecal volume and stimulation of peristalsis. Being a non-digestible sugar, it first reaches the intestine unchanged, where by osmotic effect it draws large amounts of water. Moreover, it is fermented, which can increase fecal volume and reduce the time contents remain in the colon. The bacterial fermentation of lactitol also produces short-chain fatty acids and gases, which further stimulate bowel movements. This dual action makes lactitol effective for treating constipation by both hydrating the stool and accelerating intestinal transit.

3.4 Ammonia-Reducing Mechanism in Hepatic Encephalopathy

Non-absorbable disaccharides such as lactitol reduce the effect of ammonia in the induction of hepatic encephalopathy through multiple mechanisms. They are fermented in the colon, increasing intraluminal osmolality and reducing pH. Reducing the pH prevents the conversion of ammonium to ammonia. The increase in intraluminal osmolality results in a cathartic effect in the colon. It is also suspected that NADs beneficially affect the colonic microbiota.

In patients with hepatic encephalopathy, lactitol reduces the absorption of ammonia in the gut by acidifying the colonic contents, thereby converting ammonia into ammonium ions. The resulting modifications of the colonic microbiota in favor of saccharolytic bacteria, which produce low amounts of ammonia, and the decrease in luminal pH are thought to reduce ammonia resorption from the colon.

3.5 Prebiotic Mechanism

Lactitol is known for its positive prebiotic effects on the intestinal microflora, specifically on Bifidobacteria and Lactobacilli. Simultaneously, it inhibits the growth of intestinal putrefactive bacteria, lowers pH, and reduces production and absorption of ammonia. Non-absorbable disaccharides (NADs) have been classified as prebiotics and can beneficially affect microbiota composition. Lactitol is considered the second-generation NAD and, similar to lactulose, promotes the growth of bifidobacteria and lactobacilli.

3.6 Non-Cariogenic and Low Glycemic Properties

Being not fermented in the mouth, lactitol does not contribute towards dental caries. Lactitol has a low glycemic index (GI = 5) and has a negligible effect on blood glucose or insulin levels. Lactitol is metabolized independent of insulin requirement and exhibits a glycemic index of essentially zero; it is non-cariogenic.

4. Scientific Evidence by Area of Use

4.1 Chronic Constipation

Clinical Evidence

The evidence base for lactitol in adult constipation is substantial and includes multiple randomized controlled trials and at least two systematic reviews with meta-analysis. A 2014 systematic review and meta-analysis included a total of eleven studies representing 663 distinct patients, including five single-arm studies, four RCTs comparing lactitol with lactulose, one RCT comparing lactitol with placebo, and one nonrandomized controlled trial comparing lactitol with stimulant laxatives.

The conclusion of the meta-analysis was that lactitol supplementation is well tolerated and improves symptoms of adult constipation. The efficacy and tolerance of lactitol and lactulose are similar, with a trend for more frequent stools with lactitol. Limited evidence suggests lactitol is superior to stimulant laxatives and placebo for relieving constipation symptoms.

A total of 15 human intervention studies were identified as pertinent to the EFSA health claim review. Twelve studies with various methodological limitations consistently showed that consumption of at least 10 g/day lactitol increases stool frequency; five out of six studies found that lactitol softens stool consistency.

An earlier systematic review comparing lactitol with lactulose specifically—encompassing both adult and pediatric populations—arrived at comparable conclusions. After an intensive literature search, six clinical trials were included for comparison. The relevant studies in the meta-analysis included 349 adult patients with a mean age group of 19 to 85 years and 81 children from the age group of 8 months to 16 years. In terms of efficacy, lactitol was found to be comparable to lactulose in terms of normal consistency of stool and number of bowel movements per week. Better acceptance by patients was reported with lactitol compared to lactulose (73.2% versus 26.8%). Lactitol was found to be significantly superior compared to lactulose in terms of fewer adverse events (31.20 ± 0.80% versus 62.10 ± 1.10%, p = 0.0019).

FDA Approval and Pivotal Trial

The FDA approval of lactitol was based on results of a 6-month placebo-controlled trial, a 3-month active-controlled trial, and a 1-year uncontrolled safety study. The primary efficacy analysis was based on the first 12 weeks of the 6-month treatment period among 594 patients, with 291 in the lactitol arm and 303 in the placebo arm. Significantly more patients using lactitol responded to treatment compared with placebo (25% vs 13%; 12% treatment difference; 95% confidence interval, 6.0% to 18.5%).

EFSA Health Claim

The EFSA Panel acknowledges the plausible mechanisms of action by which lactitol could exert the claimed effect. The dose of 10 g/day lactitol does not induce diarrhoea. The Panel concludes that a cause and effect relationship has been established between the consumption of lactitol and the maintenance of normal defecation. The approved wording reflects the scientific evidence: "lactitol can contribute to normal defecation." To obtain the claimed effect, 10 g of lactitol should be consumed daily. The target population is the general adult population.

Strength of Evidence

The evidence for lactitol in constipation is among the strongest of any dietary supplement application: it has achieved FDA prescription drug approval (as Pizensy), an EFSA Article 13(5) approved health claim, and consistent benefit in multiple RCTs and meta-analyses. Head-to-head comparisons with lactulose consistently show equivalent efficacy with a trend toward better tolerability and palatability for lactitol.

4.2 Hepatic Encephalopathy

Clinical Evidence

The effect of lactitol as a non-absorbable disaccharide in the treatment of chronic hepatic encephalopathy was assessed in cirrhotic patients with non-selective portosystemic anastomosis in a randomized, cross-over study. The landmark systematic review on this topic evaluated both lactulose and lactitol together as a class. A systematic review published by the Cochrane Collaboration in 2016 included 38 randomized controlled trials (RCTs) with a total of 1,826 patients and compared non-absorbable disaccharides versus placebo, with results showing a positive effect on mortality. A Cochrane review by Gluud et al., published in 2016, included 38 RCTs that investigated treatment of hepatic encephalopathy using NADs. There was a reduction in mortality in patients presenting with overt HE (RR=0.36, 95% CI 0.14–0.94, NNT=20) but not with minimal HE.

A dedicated meta-analysis comparing lactitol with other disaccharides found: meta-analysis showed that lactitol was as effective as other disaccharides in the treatment of encephalopathy, with a pooled odds ratio of 0.83 (95% confidence interval 0.38–1.82). Results were not sensitive to alternative methods of counting events. Patients experienced fewer side effects during treatment with lactitol, but the pooled odds ratio was not statistically significant. In all studies, lactitol was considered more palatable. Clinical effectiveness of lactitol in long-term treatment of chronic encephalopathy is similar to that of lactulose.

A cross-over RCT evaluated 14 cirrhotic patients with subclinical hepatic encephalopathy randomized to lactitol or lactulose for a 2-month period with psychometric testing. Patients with subclinical hepatic encephalopathy benefited from treatment with both lactitol and lactulose in terms of psychometric performance. The feasibility and benefits of long-term treatment for this condition need to be elucidated.

Lactitol (or lactulose in some countries) is often used as the first-line treatment for overt hepatic encephalopathy (OHE). Although the benefit of lactulose or lactitol is questionable when compared to the administration of antibiotics, lactitol or lactulose at levels of 30–110 g/day remains the standard treatment for hepatic encephalopathy.

Strength of Evidence

The clinical evidence for lactitol in hepatic encephalopathy is moderate to strong, with multiple RCTs and meta-analyses confirming equivalence to lactulose as a class. The Cochrane review covered the class of non-absorbable disaccharides broadly, and lactitol's individual trials contributed to that body of evidence. No RCT has demonstrated superiority of lactitol over lactulose for this indication; the advantage is primarily tolerability and palatability.

4.3 Gut Microbiota Modulation (Prebiotic Activity)

Clinical Evidence

Human clinical trials showed that lactitol decreases the populations of Bacteroides, Clostridium, coliforms, and Eubacterium. In addition, lactitol increases the production of butyrate and IgA secretion without signs of mucosal inflammation and presents symbiotic effects.

A clinical study in constipated patients found that alterations in fecal flora composition after lactitol supplementation, especially in terms of an increasing trend of Bifidobacterium, alleviated constipation symptoms. Lactitol may be a promising prebiotic candidate for patients with constipation, regardless of diabetes mellitus.

A 2021 Frontiers in Medicine study specifically examined the impact of lactitol supplementation on the microbiome of liver cirrhosis patients. The impact of lactitol on the microbiome was evident, and the lactitol-induced minor fluctuations in bile acids theoretically influenced the course of cirrhotic disease states. Lactitol, as a prebiotic, can be metabolized by intestinal bacteria to lactic acid and other natural acids. Lactitol-induced improvements in clinical outcomes require further follow-up investigations to verify the clinical relevance of microbiome alterations.

Emerging research has also begun to explore lactitol's impact in cancer-related contexts. Increasing evidence suggests that gut microbiota and their metabolites can modulate antitumor immunity; however, sufficient evidence from human studies is lacking. Researchers have begun evaluating the association of lactitol as a prebiotic with the progression of hepatocellular carcinoma (HCC). This area remains preliminary and no clinical conclusions can yet be drawn.

Strength of Evidence

The prebiotic evidence for lactitol is promising but limited in depth. The data on specific microbial shifts (increased Bifidobacterium, reduced putrefactive bacteria) comes from a modest number of human clinical trials, many of which are not specifically designed with microbiome endpoints as the primary outcome. More well-controlled trials with standardized microbiome methodology are needed to fully characterize these effects.

4.4 Dental Health (Non-Cariogenicity)

Evidence

Lactitol is not readily metabolized by the mouth bacteria, so it does not promote dental caries. Being not fermented in the mouth, it does not contribute towards dental caries, as confirmed by EFSA (2011). The non-cariogenic property arises because oral bacteria (particularly Streptococcus mutans) lack the enzymatic machinery to ferment lactitol efficiently, preventing the production of acid that demineralizes enamel. This is a well-established property of sugar alcohols as a class, supported by regulatory assessments rather than individual clinical trials of lactitol specifically.

4.5 Blood Glucose Regulation and Use in Diabetes

Evidence

Lactitol has a low glycemic index (GI = 5) and has a negligible effect on blood glucose or insulin levels. Lactitol ingestion does not increase glucose level, so it is well suited as a food ingredient for diabetics. Foods that contain lactitol as an alternative to sugar may be useful for people with diabetes as the polyol has a low glycemic index, does not raise blood glucose or insulin levels, and only contributes approximately half the calories of table sugar (2.4 kcal/g compared to 4.0 for sucrose).

These characteristics make lactitol useful as a sucrose replacer in foods marketed to diabetic consumers. However, it is important to note that the glycemic evidence is primarily derived from the known biochemistry of lactitol's minimal intestinal absorption; large-scale dedicated clinical trials specifically examining glycemic outcomes in diabetic patients are limited. The evidence is well-grounded mechanistically but relies heavily on metabolic rather than large clinical outcome data.

4.6 Emerging and Investigational Areas

Calcium Absorption

Animal studies have shown that rats fed a diet containing 5% of lactitol for two weeks displayed a significant increase of calcium absorption. However, unlike in animals, lactitol does not seem to stimulate calcium absorption in humans, and this application remains an area of preclinical observation only.

Lipid Metabolism

In some animal studies, total serum cholesterol and triglycerides were reduced equally in rats fed diets containing 7% sorbitol or lactitol. No equivalent human clinical trial data are available to confirm this effect in humans, and this finding should be regarded as preliminary, animal-derived evidence only.

5. Body Systems and Health Areas

• Gastrointestinal System: The primary locus of action. Lactitol acts as an osmotic laxative in the large intestine, increasing stool water content and frequency. It is approved by the FDA for chronic idiopathic constipation and used clinically in multiple countries for this indication.
• Hepatic System / Central Nervous System (via the Gut-Liver Axis): Hepatic encephalopathy (HE) is a neuropsychiatric disorder that may complicate liver dysfunction. Therapeutic intervention aims to reduce the production of ammonia in the colon. Lactulose and lactitol are nondigestible carbohydrates that are fermented to short-chain fatty acids in the colon. By reducing colonic ammonia and its systemic absorption, lactitol is used to prevent and treat HE.
• Gut Microbiome: Non-absorbable disaccharides have been classified as prebiotics and can beneficially affect microbiota composition. Lactitol promotes the growth of bifidobacteria and lactobacilli.
• Oral / Dental Health: Classified as non-cariogenic by regulatory agencies including EFSA; does not contribute to the formation of dental caries.
• Metabolic System: Due to minimal glycemic impact and low caloric value, it is relevant in the management of food intake for people with diabetes mellitus and those seeking reduced-calorie diets.

6. Dosage Forms and Reported Dosages

6.1 Pharmaceutical Forms

The FDA-approved prescription product (Pizensy) is an off-white crystalline powder for oral solution. Lactitol is a dry, free-flowing powder, readily soluble in aqueous solutions. It is also available as a pharmaceutical-grade ingredient (lactitol monohydrate, NF) in several countries where it is approved as an over-the-counter laxative.

6.2 Dosages Reported in Clinical Studies and Regulatory Reviews

• Chronic idiopathic constipation (FDA-approved dose): The recommended daily dosage is 20 grams, mixed with 4 to 8 ounces of water, juice, coffee, tea, or soda, preferably with meals. The dosage should be reduced to 10 grams daily in patients who have persistent loose stools.
• Maintenance of normal defecation (EFSA-approved health claim): To obtain the claimed effect, 10 g of lactitol should be consumed daily. The target population is the general adult population.
• Hepatic encephalopathy (standard treatment range): Lactitol or lactulose at levels of 30–110 g/day remains the standard treatment for hepatic encephalopathy.
• Hepatic encephalopathy (cross-over trial): In a controlled cross-over clinical trial, cirrhotic patients received lactitol at an initial dosage of 10 g/6 h during a 3-month period. Doses were adjusted to obtain two bowel movements per day.
• Diarrhea threshold (European regulatory assessment): At an intake of about 50 g per day, diarrhea may occur.

7. Safety Considerations and Drug Interactions

7.1 General Tolerability

Like other sugar alcohols, lactitol causes cramping, flatulence, and diarrhea in some individuals who consume it. These effects arise because humans lack a suitable beta-galactosidase in the upper gastrointestinal tract, and a majority of ingested lactitol reaches the large intestine, where it becomes fermentable to gut microbes and can pull water into the gut by osmosis. In the FDA pivotal trial, other less frequent adverse events included flatulence and diarrhea, and the study expressed low discontinuation rates for lactitol at 4% compared with placebo at 3%.

Extensive nonclinical studies have been performed with lactitol as support for its registration and marketing, covering basic pharmacology, genotoxicity and mutagenicity, acute and chronic studies including carcinogenicity and reproductive toxicity. Regarding carcinogenicity, life-long carcinogenicity studies indicated that Leydig cell dysplasia occurred in rats at high lactitol doses, but this was not seen in mice dosed for 24 months or dogs dosed for 12 months. This species-specific effect in some rat strains was not considered significant to humans, since ordinary milk sugar, lactose, produces a similar effect in rodents.

7.2 Contraindications

Lactitol is contraindicated in patients with a known or suspected mechanical gastrointestinal obstruction or galactosemia. Contraindications for lactitol include known hypersensitivity to the drug, bowel obstructions, and galactosemia, a rare genetic disorder in which the body cannot process the sugar galactose.

7.3 Post-Market Hypersensitivity

Hypersensitivity reactions, including rash and pruritus, have been reported during post-approval use of lactitol outside of the United States.

7.4 Drug Interactions: Absorption of Co-administered Medications

Lactitol may reduce the absorption of oral medications administered at the same time. Therefore, oral medications should be administered at least 2 hours before or after lactitol dosing. This interaction is thought to arise from accelerated gastrointestinal transit reducing the contact time available for absorption.

7.5 Drug Interactions: Specific Drug Classes

Antibiotics, particularly broad-spectrum ones, can reduce the effectiveness of lactitol by altering the gut microbiota responsible for its fermentation. Since lactitol's laxative and prebiotic effects depend entirely on colonic bacterial metabolism, any agent that depletes the colonic flora may attenuate its pharmacological action.

Concurrent use of other laxatives can exacerbate gastrointestinal side effects and lead to dehydration and electrolyte imbalances. Additional drug-class interactions that have been identified include potential interaction with neomycin (antibiotic), cardiac glycosides (digitalis), carbenoxolone (anti-ulcer agent), antifungals (amphotericin B), corticosteroids, and thiazide diuretics, as Lactitol may have interactions with these agents.

7.6 Special Populations

The safety and effectiveness of lactitol have not been established in children for the FDA-approved CIC indication. Patients with diabetes should use lactitol with caution, as it can affect blood sugar levels, albeit to a lesser extent than other sugars. The nonclinical reproductive toxicity program carried out in multiple species found no reproductive concerns at standard therapeutic doses.

7.7 Systemic Exposure

Since lactitol is extensively degraded to organic acids in the colon, there are no published studies on its blood levels after administration. Some have estimated that only 0.6% of an oral dose of lactitol is excreted in urine. Similar to what is found in animals, lactitol is extensively metabolized in the human colon, making available a significant proportion of the metabolites for colonic absorption. This minimal systemic absorption profile underlies its favorable safety record and absence of systemic pharmacokinetic drug interactions.

References

• Miller LE, Tennilä J, Ouwehand AC. Efficacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis. Clinical and Experimental Gastroenterology. 2014;7:241–248. PMC4103919.
• Patel M, Bhatt M. Lactitol or lactulose in the treatment of chronic constipation: results of a systematic review. PubMed PMID: 21510584.
• Blanc P, Daures JP, Rouillon JM, et al. Lactitol in treatment of chronic hepatic encephalopathy: a meta-analysis. PubMed PMID: 8482191.
• Vera E, Villanueva P, de Cabo M, Gschaedler A, Amaya-Llano S. Lactitol: Production, properties, and applications. Trends in Food Science and Technology. 2019;84:105–115. ScienceDirect.
• ScienceDirect Topics: Lactitol — overview from Trends in Food Science and Technology.
• EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Lactitol and the maintenance of normal defecation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal. 2015.
• DrugBank. Lactitol monohydrate. Accession Number DBSALT002935.
• Medscape. FDA OKs New Drug for Chronic Idiopathic Constipation (Pizensy/lactitol). 2020.
• Drugs.com. Pizensy (lactitol) FDA Approval History. First approved February 12, 2020.
• Vilstrup H, Amodio P, et al. Evidence-based approach to management of hepatic encephalopathy in adults. PMC9099111. 2022.
• Practical Gastroenterology. Hepatic Encephalopathy Treatment: Beyond Lactulose and Rifaximin. May 2022.
• ScienceDirect Topics: Lactitol — overview from Pharmacology, Toxicology and Pharmaceutical Science.
• Beneficial effects of lactitol on the composition of gut microbiota in constipated patients. PubMed PMID: 32483935.
• Frontiers in Medicine. Lactitol Supplementation Modulates Intestinal Microbiome in Liver Cirrhotic Patients. 2021.
• ScienceDirect. Effects of Sweeteners on the Gut Microbiota: A Review of Experimental Studies and Clinical Trials. Advances in Nutrition. 2022.
• IntechOpen. Hundred Years of Lactitol: From Hydrogenation to Food Ingredient. 2020.
• European Association of Polyol Producers (EPA). Food Legislation for Polyols.
• Tandfonline. Sweeteners permitted in the European Union: safety aspects. Food Additives and Contaminants. 2006.
• NCBI Bookshelf (DARE). Efficacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis. NBK291860.
• ClinicalTrials.gov. BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults. NCT02819297 Protocol/SAP.
• Abiru S, et al. Lactitol may improve the prognosis of hepatocellular carcinoma through the proliferation of Megasphaera as well as Bifidobacterium. Frontiers in Medicine. 2025. PMC12116508.
• Wikipedia. Lactitol. (For general classification and regulatory status overview.)